Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.

  title={Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.},
  author={Joy R. Ross and Y Saunders and P. M. Edmonds and Smitaa Patel and Karen E Broadley and Stephen R. D. Johnston},
  volume={327 7413},
OBJECTIVE To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases. DATA SOURCES Electronic databases, scanning reference lists, and consultation with experts and pharmaceutical companies. Foreign language papers were included. STUDY SELECTION Included trials were randomised controlled trials of patients with malignant disease and bone metastases who were treated with oral or intravenous bisphosphonate compared with another… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 57 extracted citations


Publications referenced by this paper.
Showing 1-10 of 39 references

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

  • SM Ali, G Hortobagyi, H Harvey, J Seaman, R Knight, L Costa
  • J Clin Oncol 2001;19:3434-7. (Accepted
  • 2003

Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial

  • DP Dearnaley, MR Sydes
  • J Clin Oncol (ASCO) 2001;A693
  • 2001

Similar Papers

Loading similar papers…